Wells Fargo lowered the firm’s price target on Procept BioRobotics (PRCT) to $51 from $58 and keeps an Overweight rating on the shares. The firm notes the company’s Q3 sales beat, but it lowered Q4 guide and provided a 2026 sales outlook with midpoint below Street. The utilization and capital spend commentary raise caution, but Wells believes that Procept commercial reorganization can support upside with an attractive valuation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PROCEPT BioRobotics: Hold Rating Amid Strong Revenue but Concerns Over Utilization and Sales Cycles
- Buy Rating Affirmed Amid Temporary Setbacks and Strategic Growth Prospects
- PROCEPT BioRobotics Reports Strong Q3 Growth and Optimistic 2026 Outlook
- Josh Jennings Reaffirms Buy Rating on PROCEPT BioRobotics Amid Strong Q3 Results and Conservative 2026 Forecast
- Procept BioRobotics sees FY26 revenue view $410M-$430M, consensus $426.95M